Copyright
©The Author(s) 2018.
World J Transplant. Feb 24, 2018; 8(1): 23-37
Published online Feb 24, 2018. doi: 10.5500/wjt.v8.i1.23
Published online Feb 24, 2018. doi: 10.5500/wjt.v8.i1.23
Predictive factors for OI | Univariate analysis | Multivariate analysis | ||||
HR | 95%CI | P-value | HR | 95%CI | P-value | |
Liver transplant (n = 30) | ||||||
% CD8+CD69+IFNγ+ T lymphocytes | 22.56 | 3.01-169.56 | 0.002 | 21.12 | 2.80-159.31 | 0.003 |
% CD4+CD69+IL-10+ T lymphocytes | 3.77 | 1.46-9.75 | 0.006 | 2.84 | 1.09-7.35 | 0.032 |
% CD4+CD69+IL-17+ T lymphocytes | 2.43 | 0.93-6.35 | 0.07 | 1.37 | 0.45-4.16 | 0.584 |
Total leukocyte | 1.08 | 0.98-1.18 | 0.111 | 0.95 | 0.78-1.17 | 0.666 |
Total lymphocytes (%) | 0.94 | 0.90-0.99 | 0.022 | 0.94 | 0.89-0.99 | 0.023 |
Total lymphocyte (cells/mm3) | 1.24 | 1.18-1.30 | 0.150 | 1.00 | 0.99-1.04 | 0.261 |
Donor age | 0.98 | 0.96-1.01 | 0.221 | 0.96 | 0.93-0.99 | 0.026 |
Recipient gender | 2.40 | 0.94-6.09 | 0.067 | 4.56 | 1.46-14.20 | 0.009 |
TRL dose (mg/d) | 0.96 | 0.87-1.10 | 0.815 | 0.82 | 0.59-1.13 | 0.230 |
MMF dose (mg/d) | 0.87 | 0.49-1.52 | 0.619 | 0.99 | 0.99-1.01 | 0.454 |
Induction therapy | 0.92 | 0.33-2.51 | 0.864 | 3.90 | 3.71-4.09 | 0.990 |
Post-transplant IS | 1.89 | 0.78-4.59 | 0.157 | 1.98 | 0.64-6.15 | 0.238 |
Acute rejection | 1.51 | 0.63-3.62 | 0.362 | 3.95 | 0.75-20.93 | 0.107 |
SALP (U/L) | 1.02 | 0.92-1.17 | 0.078 | 1.00 | 0.99-1.05 | 0.706 |
SGGT (U/L) | 1.19 | 1.13-1.25 | 0.035 | 1.01 | 0.91-1.03 | 0.333 |
Kindey transplant (n = 31) | ||||||
% CD4+CD69+IFNγ+ T lymphocytes | 2.36 | 1.28-4.33 | 0.006 | 3.29 | 1.71-6.35 | < 0.001 |
% CD4+CD69+IL-10+ T lymphocytes | 3.49 | 1.68-7.30 | 0.001 | 4.76 | 2.05-11.08 | 0.003 |
% CD8+CD69+IL-10+ T lymphocytes | 4.17 | 1.49-11.68 | 0.007 | 2.52 | 0.74-8.57 | 0.139 |
Recipient gender | 1.91 | 1.01-3.61 | 0.046 | 1.15 | 0.57-2.32 | 0.705 |
TRL dose (mg/d) | 0.95 | 0.89-1.01 | 0.112 | 0.92 | 0.85-0.99 | 0.037 |
MMF dose (mg/d) | 1.18 | 1.12-1.24 | 0.035 | 1.01 | 1.00-1.03 | 0.053 |
Induction therapy | 1.32 | 0.91-1.91 | 0.143 | 1.50 | 0.96-2.35 | 0.076 |
Post-transplant IS | 0.94 | 0.67-1.32 | 0.723 | 0.63 | 0.19-2.01 | 0.434 |
Acute rejection | 1.34 | 0.64-2.81 | 0.439 | 1.44 | 0.59-3.48 | 0.417 |
Serum creatinine | 1.02 | 1.00-1.03 | 0.014 | 1.02 | 1.00-1.04 | 0.013 |
SALP (U/L) | 0.98 | 0.97-0.99 | 0.016 | 0.98 | 0.97-1.01 | 0.074 |
SGOT (U/L) | 0.98 | 0.95-1.01 | 0.242 | 0.98 | 0.96-1.01 | 0.195 |
- Citation: Boix F, Llorente S, Eguía J, Gonzalez-Martinez G, Alfaro R, Galián JA, Campillo JA, Moya-Quiles MR, Minguela A, Pons JA, Muro M. In vitro intracellular IFNγ, IL-17 and IL-10 producing T cells correlates with the occurrence of post-transplant opportunistic infection in liver and kidney recipients. World J Transplant 2018; 8(1): 23-37
- URL: https://www.wjgnet.com/2220-3230/full/v8/i1/23.htm
- DOI: https://dx.doi.org/10.5500/wjt.v8.i1.23